SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 12th, 2024 • NeuroSense Therapeutics Ltd. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 10, 2024, between NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
NeuroSense Therapeutics Ltd. Attention: Alon Ben-Noon Building BPlacement Agreement • April 12th, 2024 • NeuroSense Therapeutics Ltd. • Pharmaceutical preparations • New York
FORM OF ORDINARY SHARES PURCHASE WARRANT NEUROSENSE THERAPEUTICS LTD.Form of Ordinary Shares • April 12th, 2024 • NeuroSense Therapeutics Ltd. • Pharmaceutical preparations
THIS ORDINARY SHARES PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 15, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from NeuroSense Therapeutics Ltd., a company organized under the laws of Israel (the “Company”), up to ______ ordinary shares, no par value per share (the “Ordinary Shares”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
